Kariva

Pregnancy Prevention

Kariva is an oral contraceptive indicated for the prevention of pregnancy. It is a combination pill that contains two types of female hormones: a progestin (desogestrel) and an estrogen (ethinyl estradiol).

How It Works

This medication prevents pregnancy by using hormones to influence the reproductive system in several ways:

• Inhibiting Ovulation: It primarily works by preventing the release of an egg from the ovaries during the menstrual cycle.
• Changing Cervical Mucus: It increases the thickness of the mucus at the opening of the uterus, making it more difficult for sperm to reach an egg.
• Altering the Uterine Lining: It changes the lining of the uterus, which makes it less likely for a fertilized egg to attach and develop.

Additional Uses and Benefits

While the primary indication is contraception, healthcare providers may prescribe combination birth control pills like Kariva because they can offer other menstrual health benefits, including:

• Regulating menstrual cycles to make periods more predictable.
• Reducing the amount of blood loss during menstruation.
• Decreasing the intensity of painful menstrual cramps.
• Lowering the risk of developing certain types of ovarian cysts.

Hormonal Action

Kariva contains two active hormones: desogestrel (a progestin) and ethinyl estradiol (an estrogen). These synthetic hormones mimic the natural hormones in a person's body to regulate the reproductive cycle and prevent conception.

Primary Mechanism

The main way Kariva prevents pregnancy is by suppressing the mid-cycle surge of luteinizing hormone and follicle-stimulating hormone. By keeping these hormone levels steady, the medication prevents ovulation, which is the release of an egg from the ovary. Without an egg, fertilization cannot occur.

Secondary Mechanisms

Kariva also provides backup methods to reduce the chance of pregnancy if ovulation were to occur:

• Cervical Mucus Changes: The progestin in the pill thickens the mucus at the opening of the uterus (the cervix). This thicker consistency makes it much harder for sperm to swim through the cervix and into the uterus.
• Uterine Lining Changes: The hormones change the lining of the uterus, also known as the endometrium. This makes the lining thinner and less prepared to support the attachment of a fertilized egg.

Common Side Effects

Many people using Kariva experience mild side effects as their body adjusts to the medication. These may include:

• Nausea, vomiting, stomach cramps, or bloating
• Breast tenderness, pain, or swelling
• Headache or migraine
• Changes in weight or appetite
• Vaginal itching or discharge
• Changes in menstrual periods or breakthrough bleeding
• Freckles or darkening of facial skin
• Decreased sex drive
• Problems with contact lenses

Serious Side Effects

While less common, Kariva can cause serious and potentially life-threatening side effects. Seek medical help immediately if you experience:

• Signs of a blood clot, such as sudden numbness or weakness, chest pain, shortness of breath, or swelling and warmth in one leg
• Symptoms of a heart attack, including pressure or pain in the chest, jaw, or shoulder
• Signs of a stroke, such as a sudden severe headache, vision changes, or slurred speech
• Liver problems, indicated by yellowing of the skin or eyes (jaundice), dark urine, or upper stomach pain
• New or worsening depression, mood swings, or sleep disturbances
• A lump in the breast
• Severe swelling in the hands, ankles, or feet
• Increased blood pressure

Smoking and Cardiovascular Risk

Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with the number of cigarettes smoked. Women who are over 35 years old and smoke should not use Kariva.

Thromboembolic Disorders

The use of combination oral contraceptives is associated with an increased risk of several serious conditions, including blood clots in the legs (venous thromboembolism), lungs (pulmonary embolism), heart attack, and stroke. Some evidence suggests that oral contraceptives containing desogestrel may have a higher risk of blood clots compared to those containing certain other progestins.

Contraindications

Kariva should not be used by individuals with certain medical histories or conditions, including:

• A history of blood clots, deep vein thrombosis, or pulmonary embolism.
• Current or past history of breast cancer or other estrogen-sensitive cancers.
• Liver tumors (benign or malignant) or active liver disease.
• Undiagnosed abnormal uterine bleeding.
• Known or suspected pregnancy.
• Uncontrolled high blood pressure.
• Migraine headaches with focal neurological symptoms (aura).

Other Precautions

Liver and Gallbladder Disease

Kariva should be discontinued if jaundice (yellowing of the skin or eyes) develops. There is also an increased risk of gallbladder disease, such as gallstones, in users of combination oral contraceptives.

Blood Pressure and Glucose Levels

Blood pressure should be monitored regularly, as some users may experience significant increases. Additionally, oral contraceptives may decrease glucose tolerance; therefore, individuals with prediabetes or diabetes should be monitored closely while taking this medication.

Bleeding Irregularities

Breakthrough bleeding and spotting may occur, especially during the first three months of use. If irregular bleeding persists or is unusually heavy, a healthcare provider should evaluate the cause to rule out pregnancy or malignancy.

Fluid Retention

Because oral contraceptives may cause some degree of fluid retention, caution is advised for individuals with conditions that might be aggravated by fluid accumulation.

Pregnancy

Kariva should not be used by individuals who are pregnant. If you become pregnant while taking this medication, you should stop taking it immediately. Studies have generally shown that the accidental use of oral contraceptives during early pregnancy does not appear to increase the risk of birth defects or cause adverse effects on fetal development.

Breastfeeding

The hormones in Kariva can pass into breast milk in small amounts. Using this medication while breastfeeding may lead to a decrease in the quantity and quality of milk produced. It is often recommended to use other forms of contraception until a child is completely weaned. You should discuss your options with a healthcare provider to determine the most appropriate timing for starting or resuming hormonal birth control after childbirth.

Dosage Forms

Kariva is available as a tablet for oral administration. It is provided in a blister dispenser designed for a monthly cycle. The tablets within the pack are divided into different phases, including active tablets with hormonal ingredients and inactive tablets. The tablets are color-coded to assist the user in following the correct daily sequence throughout the cycle.

FDA Approval and Indications

Kariva is approved by the U.S. Food and Drug Administration (FDA) as a combination oral contraceptive. It is indicated for the prevention of pregnancy in women who choose to use this method of birth control. The medication contains a combination of two hormones: desogestrel (a progestin) and ethinyl estradiol (an estrogen).

Boxed Warning

The FDA-approved labeling for Kariva includes a boxed warning concerning cigarette smoking and serious cardiovascular risks. Smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives are strongly advised not to smoke.

Regulatory Status

Kariva is a prescription-only medication. While it is subject to standard post-market surveillance by the FDA, there are currently no specific Risk Evaluation and Mitigation Strategies (REMS) required for its distribution. Healthcare providers and patients are encouraged to report any adverse events to the FDA MedWatch program to assist in ongoing safety monitoring.

Withdrawal Bleeding

Kariva is a combination oral contraceptive taken in a 28-day cycle. The pack includes active pills and a small number of inactive or low-dose pills. When you take the inactive pills at the end of the pack, the sudden drop in hormone levels causes withdrawal bleeding. While this resembles a menstrual period, it is the body's physiological response to the absence of the hormones desogestrel and ethinyl estradiol.

Stopping the Medication

You can stop taking Kariva at any time without needing to taper the dose. However, you should consider the following effects of discontinuation:

• Return of Fertility: Ovulation can occur shortly after you stop taking the pill. If you do not wish to become pregnant, you should use an alternative form of contraception immediately.
• Menstrual Cycle Changes: It may take several months for your natural menstrual cycle to return to its regular rhythm. Some individuals experience irregular periods or a temporary absence of menstruation (amenorrhea) while the body readjusts its natural hormone production.
• Return of Symptoms: If you were taking Kariva to manage specific conditions, such as heavy periods, painful cramping, or acne, those symptoms may return once the medication is stopped.

Missed Doses

If you miss one or more active pills, you may experience spotting or breakthrough bleeding. This is a form of withdrawal bleeding caused by the fluctuation of hormones in your system. Missing doses also increases the risk of pregnancy.